Oligonucleotide Therapeutics Report: What Clinical and Commercial Intelligence Reveals About the Next Phase of Market Competition

As oligonucleotides move beyond rare disease into common indications, two forces are deciding who wins: platform IP across chemistry, delivery, and the 2027-2036 expiry wave, and market execution across trials, sponsors, and licensing. - Clinical & Commercial Intelligence: who's leading the pipeline, and who's positioned to win in the clinic. Oligonucleotide therapeutics are no longer a niche rare-disease segment. With 25 approved drugs, clinical development is expanding across ASO, siRNA, CRISPR, and aptamer modalities. There is increased focus on extrahepatic delivery, reduced off-target effects, and the sponsor-collaborator model as levers for commercial differentiation. This report utilises Patsnap Synapse to examine the field through a clinical, competitive-intelligence, and BD/licensing lens, connecting approved drugs, clinical trials, sponsors, therapeutic areas, targets, geographic activity, and deal signals. The analysis shows a field entering clinical and commercial maturity, albeit unevenly across platform technologies. ASO remains the front runner whilst siRNA is catching up fast, thanks to validated liver-directed GalNAc delivery. Meanwhile, CRISPR remains predominantly early-stage by trial volume but reached an important maturity inflection in 2026 with the first positive Phase III readout for an in-vivo gene-editing candidate (lonvoguran ziclumeran), and aptamers activities remain focused on ophthalmology. The deal landscape mirrors the clinical pipeline and the maturity stage of the different technology platforms, with capital flowing toward validated assets, delivery technologies, tissue-access platforms, and modality-specific capabilities. China is also becoming an important signal source across clinical activity, sponsor formation, manufacturing capability, and early-stage partnering. The key takeaway is clear: although the modality is programmable, the market will reward selectivity, choosing where target biology, tissue delivery, indication, development path, manufacturing feasibility, and commercial value align. For clinical, BD/licensing, and CI teams, the priority is early signal detection, identifying the next meaningful asset, partner, platform, or competitive shift before it becomes obvious in the market. With fierce competition and new entrants, this report serves to provide insights on • Research activities and whitespace: from targets to indications, what are drug developers focusing on? • Clinical and deal signals based on modalities • Recent partnerships and collaborations - how you can adapt your alliance strategy globally